"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, ...

"I would say, talk to each other. Talk to other men about it. You are not the only one leaking," says Vanita Gaglani, RPT. “We hypothesized based on prior work that specifically men with low-volume ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone in patients with high-risk non–muscle invasive bladder cancer (NMIBC) found ...

"The CF for 2025 is proposed to decrease to $32.36 from $33.29 in 2024. This is a decrease of 2.80%," write Jonathan Rubenstein, MD, and Mark Painter. On July 10, 2024, the Centers for Medicare & ...

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

The updated guideline includes 25 recommendations, emphasizing risk stratification and minimizing unnecessary evaluations for low-risk patients. New guidance incorporates urine-based tumor markers for ...

The open-label, multicenter study included 157 patients enrolled in 2 cohorts: patients with carcinoma in situ (CIS) ± Ta/T1 (CIS cohort; n = 107) and patients with high-grade Ta/T1 without CIS ...

mCSPC and mHSPC refer to prostate cancer with metastases that remain responsive to hormone therapy, often used interchangeably. Both conditions involve the presence of metastases and sensitivity to ...

Based on current studies and anecdotal evidence, many of today’s urologists think it’s relatively safe to administer testosterone replacement in hypogonadal men on active surveillance or in those who ...

Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...